Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, is a potent guanylate cyclase activator. Ataciguat has potential to treat dise...
Linaclotide is an oligo-peptide agonist of guanylate cyclase 2C. It can be used for the treatment in adults of constipation-predominant irritable bowel syndrome...
Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emergin...
BAY-41-8543, with antihypertensive, is a heme-dependent stimulator of NO-independent guanylyl cyclase (sGC). In vivo, BAY 41-8543 decreases blood pressure dose-...
IWP-051 is a soluble guanylate cyclase (sGC) stimulator with EC50 of 290nM. IWP-051 shows >99% plasma protein binding, high permeability, high metabolic stabili...
Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. At the moment Phase III clinical trials investigate the ...
BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.
An experimental drug as an an activator of sGC in an NO-independent manner (Kd = 3.2 nM).
Linaclotide is a peptide agonist of guanylate cyclase 2C that is undergoing clinical trials for use in treating abdominal pain in patients with irritable bowel ...